These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 14597580)

  • 21. Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.
    Mucke HA
    IDrugs; 2009 Jun; 12(6):366-75. PubMed ID: 19517317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sitaxsentan sodium for pulmonary hypertension.
    MacIntyre IM; Dhaun N; Goddard J; Webb DJ
    Drugs Today (Barc); 2008 Aug; 44(8):585-600. PubMed ID: 18846270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sitaxsentan for treatment of pulmonary hypertension.
    Wittbrodt ET; Abubakar A
    Ann Pharmacother; 2007 Jan; 41(1):100-5. PubMed ID: 17164394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bosentan for the treatment of adult pulmonary hypertension.
    Dwyer N; Kilpatrick D
    Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Endothelin-receptor antagonists in therapy of pulmonary arterial hypertension].
    Ghofrani HA
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S177-8. PubMed ID: 19718611
    [No Abstract]   [Full Text] [Related]  

  • 26. STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials.
    Langleben D; Brock T; Dixon R; Barst R;
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S80-4. PubMed ID: 15838366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapeutic implications of endothelin antagonists for cardiovascular diseases].
    Abassi Z; Ramadan R; Schwartz H; Hoffman A
    Harefuah; 2004 Jan; 143(1):47-53, 84. PubMed ID: 14748289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sitaxsentan in the management of pulmonary arterial hypertension.
    Benedict NJ
    Am J Health Syst Pharm; 2007 Feb; 64(4):363-8. PubMed ID: 17299175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endothelin antagonism with bosentan: current status and future perspectives.
    Ono K; Matsumori A
    Cardiovasc Drug Rev; 2002; 20(1):1-18. PubMed ID: 12070530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men.
    MacIntyre IM; Dhaun N; Lilitkarntakul P; Melville V; Goddard J; Webb DJ
    Hypertension; 2010 Jun; 55(6):1406-11. PubMed ID: 20404221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
    Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
    Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.
    O'Callaghan DS; Gaine SP
    Int J Clin Pract; 2006 Apr; 60(4):475-81. PubMed ID: 16620363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist.
    Tilton RG; Munsch CL; Sherwood SJ; Chen SJ; Chen YF; Wu C; Block N; Dixon RA; Brock TA
    Pulm Pharmacol Ther; 2000; 13(2):87-97. PubMed ID: 10799286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.
    Horn EM; Widlitz AC; Barst RJ
    Expert Opin Investig Drugs; 2004 Nov; 13(11):1483-92. PubMed ID: 15500395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pulmonary hypertension and right ventricular failure. Part XI. Endothelin receptor blockers in the treatment of primary pulmonary arterial hypertension].
    Batyraliev TA; Makhmutkhodzhaev SA; Ekinsi E; Pataraia SA; Pershukov IV; Sidorenko BA; Preobrazhenskiĭ DV
    Kardiologiia; 2007; 47(7):73-82. PubMed ID: 18260899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelin antagonism in pulmonary arterial hypertension.
    Lee SH; Channick RN
    Semin Respir Crit Care Med; 2005 Aug; 26(4):402-8. PubMed ID: 16121317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade.
    Zacà V; Metra M; Danesi R; Lombardi C; Verzura G; Dei Cas L
    Ther Adv Respir Dis; 2009 Feb; 3(1):11-4. PubMed ID: 19293198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endothelin receptor blockade in congestive heart failure.
    Cheng TO
    Circulation; 2001 Oct; 104(18):E96. PubMed ID: 11684644
    [No Abstract]   [Full Text] [Related]  

  • 40. Changes in exercise capacity and cardiac performance in a series of patients with Eisenmenger's syndrome transitioned from selective to dual endothelin receptor antagonist.
    Kopeć G; Tyrka A; Miszalski-Jamka T; Mikołajczyk T; Waligóra M; Guzik T; Podolec P
    Heart Lung Circ; 2012 Nov; 21(11):671-8. PubMed ID: 22819097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.